28282033|t|PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment
28282033|a|Phosphoinositide-3-kinase and protein kinase B (PI3K - AKT) is upregulated in multiple myeloma (MM). Using a combination of short hairpin RNA (shRNA) lentivirus -mediated knockdown and pharmacologic isoform- specific inhibition we investigated the role of the PI3K p110γ (PI3Kγ) subunit in regulating MM proliferation and bone marrow microenvironment - induced MM interactions. We compared this with inhibition of the PI3K p110δ (PI3kδ) subunit and with combined PI3kδ / γ dual inhibition. We found that MM cell adhesion and migration were PI3Kγ - specific functions, with PI3kδ inhibition having no effect in MM adhesion or migration assays. At concentration of the dual PI3Kδ / γ inhibitor duvelisib, which can be achieved in vivo we saw a decrease in AKT phosphorylation at s473 after tumour activation by bone marrow stromal cells (BMSC) and interleukin-6. Moreover, after drug treatment of BMSC / tumour co-culture activation assays only dual PI3kδ / γ inhibition was able to induce MM apoptosis. shRNA lentiviral -mediated targeting of either PI3Kδ or PI3Kγ alone, or both in combination, increased survival of NSG mice xeno-transplanted with MM cells. Moreover, treatment with duvelisib reduced MM tumour burden in vivo. We report that PI3Kδ and PI3Kγ isoforms have distinct functions in MM and that combined PI3kδ / γ isoform inhibition has anti - MM activity. Here we provide a scientific rationale for trials of dual PI3kδ / γ inhibition in patients with MM.
28282033	0	5	PI3Kδ	T103	UMLS:C1450115
28282033	10	24	PI3Kγ isoforms	T103	UMLS:C2713509
28282033	63	75	pro-tumoural	T038	UMLS:C0027651
28282033	76	86	signalling	T038	UMLS:C0037083
28282033	94	110	multiple myeloma	T038	UMLS:C0026764
28282033	128	153	Phosphoinositide-3-kinase	T103	UMLS:C0044602
28282033	158	174	protein kinase B	T103	UMLS:C0164786
28282033	176	180	PI3K	T103	UMLS:C0044602
28282033	183	186	AKT	T103	UMLS:C0164786
28282033	191	202	upregulated	T038	UMLS:C0041904
28282033	206	222	multiple myeloma	T038	UMLS:C0026764
28282033	223	227	(MM)	T038	UMLS:C0026764
28282033	252	269	short hairpin RNA	T103	UMLS:C2930586
28282033	270	277	(shRNA)	T103	UMLS:C2930586
28282033	278	288	lentivirus	T005	UMLS:C0079679
28282033	299	308	knockdown	T062	UMLS:C2350567
28282033	313	344	pharmacologic isoform- specific	T103	UMLS:C0597298
28282033	388	398	PI3K p110γ	T103	UMLS:C2713509
28282033	399	406	(PI3Kγ)	T103	UMLS:C2713509
28282033	407	414	subunit	T103	UMLS:C0599220
28282033	429	431	MM	T038	UMLS:C0026764
28282033	432	445	proliferation	T038	UMLS:C0596290
28282033	450	461	bone marrow	T017	UMLS:C0005953
28282033	489	491	MM	T038	UMLS:C0026764
28282033	546	556	PI3K p110δ	T103	UMLS:C1450115
28282033	557	564	(PI3kδ)	T103	UMLS:C1450115
28282033	565	572	subunit	T103	UMLS:C0599220
28282033	591	596	PI3kδ	T103	UMLS:C1450115
28282033	599	600	γ	T103	UMLS:C2713509
28282033	632	634	MM	T038	UMLS:C0026764
28282033	635	648	cell adhesion	T038	UMLS:C0007577
28282033	653	662	migration	T038	UMLS:C1622501
28282033	668	673	PI3Kγ	T103	UMLS:C2713509
28282033	701	706	PI3kδ	T103	UMLS:C1450115
28282033	738	740	MM	T038	UMLS:C0026764
28282033	741	749	adhesion	T038	UMLS:C0007577
28282033	753	762	migration	T038	UMLS:C1622501
28282033	763	769	assays	T058	UMLS:C1510438
28282033	800	805	PI3Kδ	T103	UMLS:C1450115
28282033	808	809	γ	T103	UMLS:C2713509
28282033	820	829	duvelisib	T103	UMLS:C4079854
28282033	853	860	in vivo	T082	UMLS:C1515655
28282033	882	885	AKT	T103	UMLS:C0164786
28282033	886	901	phosphorylation	T038	UMLS:C0031715
28282033	905	909	s473	T082	UMLS:C1519254
28282033	916	922	tumour	T038	UMLS:C0027651
28282033	937	962	bone marrow stromal cells	T017	UMLS:C1640380
28282033	963	969	(BMSC)	T017	UMLS:C1640380
28282033	974	987	interleukin-6	T103	UMLS:C0021760
28282033	1005	1019	drug treatment	T058	UMLS:C0013216
28282033	1023	1027	BMSC	T017	UMLS:C1640380
28282033	1030	1036	tumour	T038	UMLS:C0027651
28282033	1037	1047	co-culture	T058	UMLS:C0430400
28282033	1059	1065	assays	T058	UMLS:C1510438
28282033	1076	1081	PI3kδ	T103	UMLS:C1450115
28282033	1084	1085	γ	T103	UMLS:C2713509
28282033	1116	1118	MM	T038	UMLS:C0026764
28282033	1119	1128	apoptosis	T038	UMLS:C0162638
28282033	1130	1135	shRNA	T103	UMLS:C2930586
28282033	1136	1146	lentiviral	T005	UMLS:C0079679
28282033	1177	1182	PI3Kδ	T103	UMLS:C1450115
28282033	1186	1191	PI3Kγ	T103	UMLS:C2713509
28282033	1245	1253	NSG mice	T204	UMLS:C0025929
28282033	1254	1271	xeno-transplanted	T103	UMLS:C0522537
28282033	1277	1279	MM	T038	UMLS:C0026764
28282033	1280	1285	cells	T017	UMLS:C0007634
28282033	1312	1321	duvelisib	T103	UMLS:C4079854
28282033	1330	1332	MM	T038	UMLS:C0026764
28282033	1333	1339	tumour	T038	UMLS:C0027651
28282033	1347	1354	in vivo	T082	UMLS:C1515655
28282033	1359	1365	report	T170	UMLS:C0684224
28282033	1371	1376	PI3Kδ	T103	UMLS:C1450115
28282033	1381	1395	PI3Kγ isoforms	T103	UMLS:C2713509
28282033	1423	1425	MM	T038	UMLS:C0026764
28282033	1444	1449	PI3kδ	T103	UMLS:C1450115
28282033	1452	1453	γ	T103	UMLS:C2713509
28282033	1454	1461	isoform	T103	UMLS:C0597298
28282033	1484	1486	MM	T038	UMLS:C0026764
28282033	1515	1535	scientific rationale	T170	UMLS:C0282574
28282033	1555	1560	PI3kδ	T103	UMLS:C1450115
28282033	1563	1564	γ	T103	UMLS:C2713509
28282033	1593	1595	MM	T038	UMLS:C0026764